+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating Enzomenib DSP-5336, an oral drug, in patients with various types of acute leukemia, including relapsed or refractory acute myeloid leukemia AML, acute lymphocytic leukemia ALL, and acute leukemia of ambiguous lineage. The study also includes patients with high-risk myelodysplastic syndromes MDS and relapsed multiple myeloma MM in selected sites. This phase 12 trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of DSP-5336 alone or combined with standard AML treatments, particularly in patients with specific genetic mutations like MLL rearrangement or NPM1 mutation. The study involves dose escalation and dose expansion of DSP-5336 administered orally. Participants may receive DSP-5336 alone or combined with standard AML regimens such as venetoclax plus azacitidine or intensive chemotherapy with cytarabine and daunorubicin 73. Different study arms include patients with or without certain medications like CYP3A4 inhibitor azoles, and those with specific genetic profiles. The trial evaluates recommended phase 2 doses for various patient groups and combination treatments. Participants will undergo assessments including monitoring for adverse events within 30 days after the last dose and evaluation of clinical responses approximately six months after treatment begins. Researchers will collect blood and bone marrow samples for genomic analysis and track drug levels in the body. Safety labs, ECGs, physical exams, and patient questionnaires will be performed throughout the study. The trial includes long-term follow-up of overall survival up to two years after treatment ends, with visits and tests scheduled to monitor health and treatment effects.

Age: 12Years +All GendersPhase 1Phase 2
104 locations
A

Actively Recruiting

Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.

Age: 40Years +All GendersPhase 2
367 locations
E

Actively Recruiting

Researchers are investigating how emotional distress ED affects treatment outcomes in patients with metastatic breast cancer mBC who are receiving first-line therapies. This study focuses on the impact of baseline emotional distress on the effectiveness of various treatments according to breast cancer subtypes. Emotional distress is common among breast cancer patients and has been linked to poorer treatment adherence and quality of life, but its role in metastatic breast cancer treatment success is not well understood. Participants will be grouped based on their breast cancer subtype and receive standard first-line treatments accordingly triple-negative PD-L1 positive patients receive chemotherapy with immune checkpoint inhibitors, triple-negative PD-L1 negative patients receive chemotherapy alone, HR-positiveHER2-negative patients receive a CDK46 inhibitor plus endocrine therapy, and HER2-positive patients receive chemotherapy combined with trastuzumab and pertuzumab. Emotional distress and quality of life will be assessed through questionnaires at baseline and during treatment. During the study, patients will complete specific questionnaires to measure emotional distress, quality of life, and fear of cancer progression. Researchers will monitor progression-free survival and objective response rates over two years, comparing outcomes based on emotional distress levels at the start and early in treatment. Quality of life and psychological factors will also be evaluated over three months. All participants must provide informed consent and meet eligibility criteria before joining.

Age: 18Years +All Genders
37 locations
I

Actively Recruiting

Researchers are comparing high intensity reinduction chemotherapy with low intensity therapies in patients with relapsed or refractory Acute Myeloid Leukemia AML who are in their first or second relapse. This pragmatic, randomized clinical trial aims to evaluate the clinical benefits and safety of these treatment approaches. The study is funded by the European Commission and seeks to provide real-world insights into personalized treatment options for AML. Participants will be assigned to one of two groups one receiving low intensity therapies, which involve innovative and targeted drugs alone or in combinations with less-toxic agents the other receiving high intensity chemotherapy regimens, including various high-dose chemotherapy combinations. Both treatment types may be combined with antibodies or targeted agents as per local practice. The study follows a clinical-oriented approach to compare these strategies. During the trial, participants will undergo treatment and regular evaluations to monitor their response, quality of life, and safety over a period of 36 months. Researchers will assess event-free survival, overall survival, treatment responses, patient-reported quality of life, and safety outcomes. The study design includes randomization without blinding and covers a follow-up period extending up to the study completion in 2028.

Age: 18Years +All GendersPhase 3
51 locations
S

Actively Recruiting

Researchers are conducting a prospective observational study called STREAM that collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia AML. This study aims to gather real-world information on treatment outcomes across Europe, including pediatric, adult, and elderly patients, as well as those with rare mutations or post-transplant relapse. The goal is to better understand the disease and support future clinical trials by monitoring various patient groups in different care settings. Participants will be registered into the STREAM platform where baseline and follow-up data will be recorded. Patients are followed according to standard clinical practice for up to 4 years. This study does not involve experimental treatments but collects detailed information on diagnosis methods, treatment options, and patient outcomes to evaluate overall survival and other clinical measures. During the study, researchers will track outcomes such as overall survival, remission rate, event-free survival, relapse-free survival, and transplant rate over 8 years. They will also analyze associations between clinical and molecular parameters and patient outcomes. Data collection includes medical records and follow-up visits based on routine care, supporting the development of future targeted therapies and clinical trials for relapsed or refractory AML.

Age: 6Years +All Genders
41 locations
P

Actively Recruiting

Researchers are studying children with Autism Spectrum Disorders ASD aged 0 to 11 years to evaluate the impact of ongoing real-life treatments provided in three different National Health Service settings. This observational study aims to explore multidimensional and comprehensive outcome measures that reflect global functioning, quality of life, and shared decision making. The study addresses the need for more integrated and long-term evaluation tools in ASD care, following Italian national guidelines. Participants will continue their usual treatments in line with national autism guidelines at different health facilities, representing diverse service organizations. New outcome tools, including the Child and Adolescent Needs and Strengths CANS scale, the Developmental Disabilities-Child Global Assessment Scale DD-CGAS, and the Pediatric Quality of Life Inventory PedsQL, will be used to assess changes pre- and post-intervention. The study will investigate correlations between these tools and identify clusters related to needs and strengths. During the study, children will undergo assessments using these scales from March 2025 to August 2026 to measure global functioning, quality of life, and evolving needs. Researchers will evaluate the acceptability and usefulness of the outcome tools for clinicians, patients, and families, as well as their sustainability in daily practice. The primary outcome focuses on identifying specific CANS item clusters that differentiate user profiles at baseline, with several secondary outcomes measuring changes over time.

Age: 0Years - 11YearsAll Genders
3 locations
E

Actively Recruiting

Researchers are investigating the use of surovatamig AZD0486 monotherapy as a treatment for adults with relapsed or refractory B-cell non-Hodgkin lymphoma NHL, specifically follicular lymphoma FL and large B-cell lymphoma LBCL. This Phase 2, global, multi-center, open-label study aims to evaluate the efficacy, safety, and tolerability of surovatamig in participants who have already received at least two prior therapies. Participants will receive surovatamig administered as an intravenous infusion at the recommended Phase 2 dose RP2D. The study consists of two modules Module 1 focuses on relapsed or refractory FL, and Module 2 targets relapsed or refractory LBCL. The treatment is given in cycles, and researchers will monitor patients closely during and after administration to assess response and safety. During the study, participants will undergo various assessments including laboratory tests, imaging to measure lymphoma lesions, and evaluations of treatment response. Researchers will track adverse events and drug levels over time. The primary outcome is the overall response rate, evaluated for up to 24 months in Module 1 and 12 months in Module 2. Secondary outcomes include duration of response, survival measures, and quality of life. Follow-up may continue for up to five years to monitor long-term effects and treatment impact.

Age: 18Years +All GendersPhase 2
94 locations